Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Technology appraisal guidance
Reference number: TA456
Published:
The provisional guidance on the use of the above technology was amended following a request for factual correction to the final appraisal. Because the change affected section 1 of the document, a second FAD was issued